It has long been hypothesized that increased adiposity would be associated with decreased vasomotor symptoms during menopause because of conversion of androgens to estrogens in body fat. However, recent thermoregulatory models have postulated that increased adipose tissue would be associated with a greater likelihood of vasomotor symptoms. The authors evaluated these hypotheses in the Study of Women's Health Across the Nation, a multiethnic, community-based observational study of US women transitioning through menopause. The sample included 1,776 women aged 47-59 years with an intact uterus and at least one ovary who completed bioelectrical impedance analysis for assessment of body composition at the sixth annual study visit (2002-2004). Assessments also included reported vasomotor symptoms (hot flashes, night sweats) and serum levels of follicle-stimulating hormone, estradiol, and sex hormone-binding globulin-adjusted estradiol (free estradiol index). Results indicated that a higher percentage of body fat was associated with increased odds of reporting vasomotor symptoms (per standard deviation increase in percent body fat, odds ratio = 1.27, 95% confidence interval: 1.14, 1.42) in age- and site-adjusted models. Associations persisted in fully adjusted models and were not reduced when models included reproductive hormones. These findings support a thermoregulatory model of vasomotor symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/aje/kwm244 | DOI Listing |
Semin Reprod Med
January 2025
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan.
Female reproductive aging often affects women's emotional, physical, and physiological well-being. Ovarian aging is characterized by fluctuations in reproductive hormones and determines the age at which menopause occurs. Understanding potentially modifiable factors that influence this process is essential for addressing health disparities, improving quality of life, and informing relevant public health strategies.
View Article and Find Full Text PDFMenopause
February 2025
From the Indiana University School of Nursing, Indianapolis, Indiana.
Eur J Med Res
January 2025
Faculty of Medicine, Menoufia University, Yassin Abdelghaffar Street From Gamal Abdelnaser Street, Shebin Al-Kom, 32511, Menoufia, Egypt.
Background: Postmenopausal women are more likely to experience vasomotor symptoms (VMS), such as heat sensation and sweating. Recent trials have investigated fezolinetant in the treatment of VMS in postmenopausal women. Our study aims to conduct a meta-analysis of these trials in order to estimate fezolinetant's effectiveness and safety in the management of VMS in postmenopausal women.
View Article and Find Full Text PDFJ Physiol Sci
January 2025
Department of Biomedical Engineering, Toyo University, Kawagoe, Japan.
The purpose of this study was to clarify sex differences in the inhibition of sympathetic vasomotor outflow which is caused by the loading of cardiopulmonary baroreceptors. Ten young males and ten age-matched females participated. The participants underwent a passive leg raising (PLR) test wherein they were positioned supine (baseline, 0º), and their lower limbs were lifted passively at 10º, 20º, 30º, and 40º.
View Article and Find Full Text PDFMenopause
January 2025
From the Infertility and Health Reproductive Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Objective: Menopausal symptoms can significantly impact women's quality of life. Herbal interventions like Matricaria chamomilla (chamomile) have been suggested as potential remedies. However, their efficacy and safety remain underexplored.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!